Abstract Objective: To report the incidence of postattenuation seizures (PAS) in dogs that underwent single congenital extrahepatic portosystemic shunt (cEHPSS) attenuation and to compare incidence of PAS in dogs that either did or did not receive prophylactic treatment with levetiracetam (LEV). Study design: Multi-institutional retrospective study. Population: Nine hundred forty dogs. Methods: Medical records were reviewed to identify dogs that underwent surgical attenuation of a single cEHPSS from January 2005 through July 2017 and developed PAS within 7 days postoperatively. Dogs were divided into 3 groups: no LEV (LEV−); LEV at ≥15 mg/kg every 8 hours for ≥24 hours preoperatively or a 60 mg/kg intravenous loading dose perioperatively, followed by ≥15 mg/kg every 8 hours postoperatively (LEV1); and LEV at <15 mg/kg every 8 hours, for <24 hours preoperatively, or continued at <15 mg/kg every 8 hours postoperatively (LEV2).
Results: Seventy-five (8.0%) dogs developed PAS. Incidence of PAS was 35 of 523 (6.7%), 21 of 188 (11.2%), and 19 of 228 (8.3%) in groups LEV-, LEV1, and LEV2, respectively. This difference was not statistically significant (P = .14). No differences between groups of dogs that seized with respect to investigated variables were identified. Conclusion: The overall incidence of PAS was low (8%). Prophylactic treatment with LEV according to the protocols that were investigated in our study was not associated with a reduced incidence of PAS. Clinical significance: Prophylactic treatment with LEV does not afford protection against development of PAS. Surgically treated dogs should continue to be monitored closely during the first 7 days postoperatively for seizures.
| INTRODUCTION
Development of postattenuation seizures (PAS) is a devastating and frequently fatal postoperative complication in dogs undergoing surgical attenuation of congenital portosystemic shunts, with survival rates ranging from 0%-53.8% in previous studies that included more than 3 affected dogs. [1] [2] [3] [4] [5] [6] [7] Incidence of PAS has been reported as high as 18.2% 1,2,4-8 and up to 4.7%-8.1% in more recent literature. 6, 7 Seizures typically occur within 96 hours postoperatively and have been reported after congenital extrahepatic portosystemic shunt (cEHPSS) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] and, less commonly, intrahepatic portosystemic shunt (cIHPSS) attenuation. 13, 14, [19] [20] [21] [22] [23] [24] [25] Such seizures appear different from those observed preoperatively in that they are often very challenging to control, often being refractory to typical first-line antiseizure medications. [1] [2] [3] [4] [5] [6] [7] [8] [10] [11] [12] [14] [15] [16] 21, 22 The etiopathogenesis of PAS remains unknown. The most commonly cited cause is a decrease in systemic concentrations of endogenous benzodiazepines/benzodiazepine-like substances from the portal circulation after shunt attenuation. 26 Other suggested causes include hypoglycemia, hepatic encephalopathy, hypoxemia/hypoxic brain injury, systemic hypertension, electrolyte disturbances, and concurrent brain disease. 2, 3, 17, 18, 21 None of these, however, have been consistently identified in affected dogs. [1] [2] [3] [6] [7] [8] [9] [10] [11] 15, 17, 18, 21, 22 Prolonged surgical and anesthetic times and intraoperative hypotension have anecdotally been suggested to be implicated in PAS; however, these are not supported by results from a recent study. 6 Risk factors for development of PAS are not well established. 7 Development of seizures has not been prevented by partial ligation, [1] [2] [3] 9, 12, 20, 21 use of delayed attenuation devices, [3] [4] [5] 10, 12, 14, 15, 17, 22, 23 or coil embolization. 24, 25 In a recent study, increasing age and the presence of hepatic encephalopathy (HE) immediately preoperatively were identified as risk factors for development of postattenuation neurologic signs (PANS) and PAS. 7 Matushek et al 1 reported
that 40% of dogs that developed PAS had a history of preoperative HE. In a study by Tisdall et al, 3 dogs with cEHPSS were significantly more likely to develop PANS compared with dogs with cIHPSS; however, this is not supported by 2 more recent studies. 7, 14 In the study by Tisdall et al, 3 there
was also a trend toward dogs with portoazygous shunts being at greater risk of PANS compared with those with other shunt morphologies. Certain breeds have been suggested to be at increased risk of PANS/PAS, including pugs, 3, 10, 17 Jack Russell terriers, 14 and Maltese terriers. 9 Efforts to reduce the incidence of PAS in dogs undergoing cEHPSS attenuation have included pretreatment with phenobarbital, 3, 10, 15 potassium bromide, 4, 23 and levetiracetam (LEV). [5] [6] [7] In one study, 3 no dog that received prophylactic phenobarbital experienced postoperative generalized seizures; however, the overall incidence of PANS was not significantly decreased. Development of seizures has also been described after pretreatment with potassium bromide. 4, 23 There are conflicting reports in the literature regarding the possible protective effects of LEV against development of PAS. [5] [6] [7] Findings of a retrospective study by Fryer et al in 2011 led to a paradigm shift in the preoperative management of dogs undergoing shunt attenuation in many institutions. In that study, no dog that received LEV at a dose of 20 mg/kg every 8 hours for a minimum of 24 hours preoperatively experienced PAS. Conversely, 5% of dogs that did not receive LEV pretreatment experienced PAS, leading to a decision for humane euthanasia. 5 These results, however, are not supported by 2 more recent studies 6, 7 in which pretreatment with LEV was not associated with reduced incidence of PAS. Therefore, the objectives of our study were (1) to report the incidence of PAS in a large cohort of dogs that underwent cEHPSS attenuation and (2) to compare incidence of PAS in dogs that either did or did not receive prophylactic LEV. Our hypothesis was that there would be no significant difference in incidence of PAS among dogs that either did or did not receive prophylactic LEV. Dogs that received less than every 8 hours administration of LEV (regardless of accompanying dose) were assigned to group LEV2. Postoperative duration of LEV was also recorded for all dogs in groups LEV1 and LEV2.
| MATERIALS AND METHODS

| Inclusion and exclusion criteria
| Dogs that developed PAS
Additional data retrieved only from the medical record of dogs that developed PAS within 7 days postoperatively and compared between groups of affected dogs included breed, age, sex/neuter status, and body weight at time of surgery; shunt morphology (portocaval, portoazygous, or portophrenic); concurrent/historical conditions at presentation; presence of preoperative neurologic signs; presence of preoperative seizures; method of shunt identification (abdominal ultrasound, computed tomography angiography [CTA], scintigraphy, intraoperative portovenography [IOPV], MRI); details of preoperative medical management (diet, antimicrobial, lactulose); method of shunt attenuation (SL, TFB, ARC) and degree of acute intraoperative attenuation (none, partial, or complete); type and timing of PAS; and electrolyte (sodium, potassium, and chloride), glucose, and ammonia concentrations about the time of PAS occurrence (when available). Dogs that received preoperative antimicrobial and lactulose medication were recorded as either having received these medications for a minimum of 1 week prior to surgery or not. For dogs that received prophylactic LEV, timing of the last preoperative dose in relation to commencement of surgery and the most recently administered dose relative to seizure onset (in hours) were recorded. Timing of occurrence of seizures was recorded in hours when available or converted to hours if recorded in days. Dogs were stratified as having experienced partial/focal seizures only or as having experienced generalized seizures with or without partial/focal seizures. For dogs that developed PAS, short-term survival, defined as survival to 30 days, was also recorded.
| Statistical analysis
Continuous variables were tested for normality by using the Shapiro-Wilk test. Normally distributed continuous data are presented as mean and standard deviation. Nonnormally distributed continuous data are presented as median and range. Categorical variables are presented as frequency and percentages (with 95% CI). Normally distributed continuous data were compared among groups of dogs that experienced PAS by using 1-way ANOVA. Nonnormally distributed continuous data were compared by using the Kruskal-Wallis and MannWhitney U tests, whereas categorical variables were compared among PAS groups by using Pearson's χ 2 test. A power analysis based on a modification of previously published data 5 was performed. In that study, 5 dogs that did and did not receive pretreatment with LEV had a 0% and 5% incidence of PAS, respectively. With an incidence of 1% and 5%, respectively, a total of 284 dogs per group would be required to show a true difference between 2 groups if a difference were to exist, with a power of 80% and an α of .05. P < .05 was considered significant. Statistical analyses were performed in SPSS Statistics version 24 (IBM, Armonk, New York).
| RESULTS
In total, 940 dogs satisfied the inclusion criteria and were included in the study. Among these, 75 (8.0%; CI:
6.4%-9.9%) dogs developed PAS. Details of 3 dogs were partially reported previously. 15, 16 Incidence of PAS within individual institutions is listed in Table 1 .
| Group LEV−
Five hundred twenty-three dogs were included in group LEV−; 35 (6.7%; CI: 4.9-9.2%) dogs developed PAS.
| Group LEV1
One hundred eighty-eight dogs were included in group LEV1; 21 (11.2%; CI: 7.4%-16.5%) dogs developed PAS. All 21 dogs were still receiving LEV at the time of PAS occurrence. Median postoperative duration of LEV of 167 dogs in group LEV1 that did not develop PAS was 10 days (range, 1-760), recorded as indefinitely (n = 1), not recorded (n = 2). Among those that developed PAS (n = 21), duration of pretreatment (excluding 2 dogs that received a 60 mg/kg intravenous loading dose perioperatively) was 6 days (range, Shunt morphology (n) Portocaval (26) Portocaval (14) Portocaval (13) .97
Portoazygous (5) Portoazygous (4) Portoazygous (4) Portophrenic (3) Portophrenic (2) Portophrenic (2) Presence of concurrent/historical conditions at presentation, n (%) (i) Method and (ii) degree of SL (13) TFB ( dogs that seized with respect to variables investigated were identified ( Table 2 ).
| Demographics of dogs that developed PAS
The most common breeds were mixed breed (n = 16), bichon frise (n = 10), Yorkshire terrier (n = 9), shih tzu (n = 8), and pug (n = 8). Median age was 34 months (range, 4-115). There were 25 neutered males, 22 spayed females, 13 intact males, 13 intact females, and 2 unspecified females. Median weight was 6.2 kg (range, 2.0-21.0).
| Method of shunt identification and shunt morphology of dogs that developed PAS
Method of shunt identification included abdominal ultrasound (n = 61; 81.3%), CTA (n = 21; 28.0%), IOPV (n = 17; 22.7%), scintigraphy (n = 1; 1.3%), and MRI (n = 1; 1.3%). Information regarding shunt morphology was available for 73 of 75 (97.3%) dogs. Overall, shunt types included portocaval (n = 53), portoazygous (n = 13), and portophrenic (n = 7).
| Concurrent/historical conditions at presentation in dogs that developed PAS
Concurrent/historical conditions were recorded in 25 of 75 (33.3%) dogs and most commonly included urolithiasis (n = 17), urinary tract infection (n = 6), and cardiac murmur (n = 3). Two dogs had previously undergone cEHPSS attenuation but did not develop PAS after initial surgery.
| Incidence of preoperative neurologic signs and seizures in dogs that developed PAS
Preoperative neurologic signs were recorded in 61 of 75 (81.3%) dogs and most commonly included lethargy (n = 28), pacing/compulsive walking (n = 12), dullness (n = 10), head pressing (n = 10), ataxia (n = 10), abnormal/change in behavior (n = 10), hypersalivation/drooling (n = 9), circling (n = 5), (possible) blindness (n = 4), disorientation (n = 4), sleepy/inappropriate sleeping/sleeps a lot (n = 4), depression (n = 4), and 2 each of twitching, 
| Method and degree of acute intraoperative shunt attenuation in dogs that developed PAS
Shunts were attenuated by using TFB (n = 30; 40.0%), SL (n = 23; 30.7%), ARC (n = 21; 28.0%), or a combination of SL and TFB (n = 1; 1.3%). 
| Type and timing of PAS
| DISCUSSION
The main findings of this study are (1) that the overall incidence of PAS was low (8%) and similar to that reported in recent literature 6, 7 and (2) that prophylactic treatment with LEV, at either ≥15 mg/kg every 8 hours for ≥24 hours preoperatively or a 60 mg/kg intravenous loading dose perioperatively with continuation postoperatively at ≥15 mg/kg every 8 hours (group LEV1) or other less standardized LEV protocols (LEV2), did not result in a reduced incidence of PAS compared with dogs that did not receive any prophylactic LEV (group LEV−). No significant differences were identified between groups of dogs that seized with respect to signalment; shunt morphology; concurrent conditions; incidence of preoperative neurologic signs and seizures; preoperative medical management; method and degree of shunt attenuation; type and timing of PAS; electrolyte, ammonia and glucose concentrations at the time of seizures; and shortterm survival. The results of this study provide evidence to corroborate findings of 2 recent studies 6,7 that prophylactic treatment with LEV does not afford protection against development of PAS in contrast to what has been suggested by Fryer et al. 5 In a pharmacokinetic study by Moore et al, 27 administration of LEV at 20 mg/kg every 8 hours consistently produced plasma LEV concentrations within the 5-45 μg/ml therapeutic range in healthy dogs. This therapeutic range is based on extrapolations from humans; the plasma LEV concentrations required to prevent seizures in dogs undergoing cEHPSS attenuation is unknown. In our study, we included dogs that received LEV at ≥15 mg/kg every 8 hours in group LEV1 to accommodate for expected small deviations from the recommended 20 mg/kg dose because of tablet size limitations. The median preoperative dose of LEV in dogs that developed PAS in group LEV1 was 20 mg/kg, with over 75% of dogs receiving ≥20 mg/kg every 8 hours preoperatively and postoperatively. In the study by Moore et al, 27 mean terminal half-life of LEV was 3.6 hours, which resulted in steady state after 18 hours (K. Muñana, personal communication, March 2018). These pharmacokinetic data provide evidence to support that steady-state should have been achieved at the time of surgery in dogs in group LEV1 in our study. Furthermore, these data provide evidence to suggest that there is no benefit in pretreating dogs for >24 hours prior to surgery. We also included in group LEV1 dogs that received a 60 mg/kg intravenous loading dose of LEV perioperatively. According to a pharmacokinetic study, 28 administration of a single intravenous 60 mg/kg loading dose resulted in plasma LEV concentrations within or above the recommended therapeutic range for at least 8 hours. This was followed with postoperative administration of LEV at a dose of ≥15 mg/kg every 8 hours in such dogs in group LEV1 in our study. We did not include in our study dogs that received other antiseizure medication concurrently with LEV because of expected alterations in the pharmacokinetics of LEV. 29, 30 The median age (34 months) of dogs that developed PAS in our study was greater than the expected age of dogs undergoing cEHPSS attenuation. 31 This observation that older dogs may be at increased risk of experiencing PANS/PAS has been made by several other investigators. [1] [2] [3] [4] 7, 17 In a recent study by Strickland et al, 7 increasing age was found to be a significant risk factor for development of PANS and PAS. Postoperative administration of LEV in our study was very variable, reflecting its multicenter nature, with similar variation reported in the literature. [5] [6] [7] In a recent study by Strickland et al, 7 all dogs that were administered LEV received the drug for a minimum of 5 days postoperatively. In the study by Fryer et al, 5 median postoperative duration of LEV was 33 days; however, some dogs appear not to have received any postoperative LEV, with the authors placing emphasis on pretreatment of dogs. In the study by Brunson et al, 6 the authors similarly do not specifically report postoperative duration of LEV. According to pharmacokinetic data by Moore et al, 27 dogs that do not have continued administration of LEV postoperatively would be expected to have drug plasma concentrations fall below the recommended therapeutic range after approximately 12 hours. In our study, all dogs that developed PAS in groups LEV1 and LEV2 were still receiving LEV at the time of seizure occurrence. We acknowledge that there is an important reliance on owners to administer antiseizure medication at home. We defined PAS as seizures that occurred within 7 days postoperatively, in accordance with what has been reported in the literature.
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Occurrence of seizures was recorded up to 128 hours postoperatively in our study. It would therefore seem intuitive, when considering prophylactically treating dogs with LEV, to continue postoperative administration for a minimum of 6 days.
In the current study, we did not exclude dogs that developed PAS that had a history of preoperative seizures. In a recent study by Brunson et al, 6 dogs with a history of preoperative seizure activity that subsequently developed PAS had a significantly increased probability of survival compared to those that had not. It is possible that both subsets did not experience seizures of the same etiopathogenesis, although this is purely speculative. It is also possible that some dogs that had a history of preoperative seizures had continuation of these seizures postoperatively. Dogs that had a history of preoperative neurologic signs were also not excluded in our study. Strickland et al 7 reported that the presence of HE immediately preoperatively was a risk factor for development of PANS and PAS. In a study by Matushek et al, 1 40% of dogs that experienced PAS had a history of preoperative HE. We also did not exclude dogs in which hypoglycemia, hyperammonemia, or electrolyte derangements were identified at the time of PAS occurrence. Although it is possible that some dogs may have experienced seizures directly attributable to these disturbances, we suspected that there would be an even distribution of such cases across all 3 groups, which was subsequently confirmed by statistical comparisons. None of these derangements have consistently been identified within or among previous studies, [1] [2] [3] [4] [5] [6] [8] [9] [10] [11] 15, 17, 21, 22 nor has correction of such abnormalities been found to abolish seizure activity in all cases. [1] [2] [3] [4] Seizures have also been demonstrated to occur in the face of ammonia concentrations lower than those obtained preoperatively 1, 2, 11 and at glucose concentrations, albeit decreased, not typically associated with seizure activity. 2, 4 These clinicopathologic variables unfortunately were not available for review for all dogs in our study, which may have led to underestimation of the incidence of these derangements overall and within individual PAS groups. We acknowledge a number of important limitations in this study. This was a retrospective study, in which accuracy of recorded data depends on accuracy and completeness of the medical records. Details concerning variables other than administration of LEV were not available for all 940 dogs in this study, and it is possible that a confounding factor may have biased 1 or more groups toward a higher rate of PAS. This study did not include institutions that biased administration of LEV toward dogs perceived to be at greater risk of PAS (eg, older dogs or those that had a history of preoperative neurologic signs or seizures). Therefore, the authors speculate that a homogenous population of dogs exists overall within the 3 groups. Moreover, were it the case that the LEV groups are in fact biased toward a higher proportion of at-risk dogs, these are the dogs clinicians would be expected to select for prophylactic treatment with LEV; however, 8.3%-11.2% of these treated dogs continued to develop PAS in our study. Because of the nonprospective nature of this study, administration of LEV within individual institutions was not randomized, with the decision to pretreat with LEV based on the attending clinician's belief regarding its possible protective effects against development of PAS. All dogs that developed PAS in groups LEV1 and LEV2 were still receiving LEV at the time of seizure occurrence; however, exact timing of the last (most recent) dose relative to seizure onset could not be verified in all cases. If this were greater than the recommended 8-hour dosing interval, PAS may have developed due to inadequate plasma LEV concentrations rather than a lack of efficacy of the drug. A power analysis based on a modification of results from Fryer et al 5 indicated that 284 dogs would be required in groups LEV− and LEV1 to show a true difference in incidence of PAS if it were to exist. Because of administration of less standardized LEV protocols (group LEV2) within institutions in our study, a total of only 188 dogs met the inclusion criteria for group LEV1. It is possible that this shortfall may have resulted in a type II error in our study and that a small difference does exist between groups but could not be detected. Additional prospective randomized studies are required to confirm our results. The incidence of PAS in group LEV1 was almost twice that in group LEV−, and it is possible that this is reflective of the relatively smaller number of dogs in group LEV1. Measurement of plasma LEV concentrations was not performed in our study and is not routinely performed in clinical practice. We excluded dogs that died or were euthanized within 24 hours postoperatively for reasons unrelated to seizure activity. This ideally would have been extended to at least 5 days; however, several dogs were discharged prior to 5 days postoperatively after an uncomplicated recovery, so we could not guarantee that they did not die of other causes within this time frame and, thus, were not given the opportunity to develop PAS. Because of this study's retrospective nature, the categorization of seizure type as focal or generalized reflects what was recorded in the medical record. Serum electrolyte, ammonia, and glucose concentrations were not available for review for all dogs in this study, and this will have affected the results of our study. Furthermore, because of this study's multicenter nature, in cases where clinicopathologic variables were available, these variables were obtained from several different analyzers. Finally, we acknowledge the subjectivity in assessing the degree of shunt attenuation intraoperatively, particularly concerning partial attenuation. 
